Business context and reporting period
Issuer discrepancy: The supplied filing is ARCA biopharma, Inc.’s Form 10-Q, not an Oruka Therapeutics, Inc. filing. It covers the quarter and nine months ended September 30, 2016; the report was signed November 14, 2016.
ARCA is a clinical-stage biopharmaceutical company with no product revenue. Its lead candidate, Gencaro (bucindolol hydrochloride), is being studied for atrial fibrillation in patients with heart failure with reduced ejection fraction. The GENETIC-AF adaptive Phase 2B/Phase 3 trial compares Gencaro with Toprol XL and selects patients with a specified genotype.
Financial results and position
Amounts below are in millions of dollars, except per-share data. The filing reports no revenue; profit margins are therefore not meaningful.
| Metric | Q3 2016 | Q3 2015 | Nine months 2016 | Nine months 2015 |
|---|---|---|---|---|
| Research and development expense | $3.720 | $1.716 | $9.227 | $5.170 |
| General and administrative expense | $0.992 | $1.101 | $3.094 | $3.110 |
| Total costs and expenses | $4.712 | $2.817 | $12.321 | $8.280 |
| Net loss | $4.659 | $2.814 | $12.200 | $8.277 |
| Net loss per share | $0.51 | $0.31 | $1.35 | $1.54 |
- Cash and cash equivalents were $8.095 million at September 30, 2016, versus $38.802 million at December 31, 2015. Marketable securities totaled $19.340 million, bringing cash, cash equivalents and securities to $27.435 million.
- Operating cash use was $11.145 million for the first nine months of 2016, compared with $7.914 million in the prior-year period. Investing cash use was $19.562 million, primarily reflecting purchases of marketable securities; there was no financing cash inflow in 2016.
- Total assets were $28.679 million and total liabilities were $2.199 million. The filing reports no debt balance; interest expense was zero for the 2016 periods presented.
- Management said available cash and cash equivalents were expected to fund operations at the projected cost structure through at least the end of 2017. This outlook is subject to uncertainty, and further financing is needed for Phase 3 and subsequent development.
Changes versus the prior comparable periods
- Q3 net loss increased to $4.659 million from $2.814 million; nine-month net loss increased to $12.200 million from $8.277 million. The increase primarily reflected higher R&D spending on GENETIC-AF.
- R&D expense rose about $2.0 million in Q3 and $4.1 million year to date. The company attributed the increases to trial activity, patient enrollment, European expansion, personnel, and clinical-material production and testing.
- G&A expense was broadly unchanged year to date. Q3 G&A declined modestly, partly because the prior-year period included reverse-stock-split costs.
- Cash, cash equivalents and marketable securities declined by about $11.4 million from year-end 2015. The reported $30.7 million decrease in cash alone includes the shift of funds into marketable securities.
Outlook, risks and notable items
- Management projected reaching 150 patients enrolled in GENETIC-AF in Q1 2017 and receiving the DSMB interim-analysis recommendation in Q3 2017. The DSMB could recommend proceeding to Phase 3, completing the study as Phase 2B, or stopping for futility.
- The planned trial is approximately 620 patients if it advances to Phase 3. Continuing into Phase 3 and pursuing possible FDA approval will require additional capital or a strategic transaction; financing may dilute shareholders or may not be available on acceptable terms.
- Key risks include enrollment delays, trial outcomes and safety, regulatory approval, companion-diagnostic approval and availability, reliance on CROs and other collaborators, manufacturing, intellectual-property protection, Nasdaq listing requirements, and the company’s ability to raise capital or complete a strategic transaction.
- The filing states the company has generated no revenue and has incurred substantial losses and negative operating cash flows. It warns that insufficient funding or failure to secure a strategic transaction could force reduced or discontinued development or operations.
- Under its CPEC license, potential obligations include an $8 million milestone after U.S. FDA approval, up to $5 million for European and Japanese approvals, and royalties of 12.5%–25% of related product revenue, subject to specified terms.
- The company reported $329,000 of nine-month 2016 expense under unrestricted research grants to its CEO’s academic laboratory, compared with $277,000 in the prior-year period. It reported no legal proceedings and stated disclosure controls were effective at a reasonable level of assurance.
Important facts for investors to verify
- Confirm the issuer: the supplied document identifies ARCA biopharma, Inc., despite the request metadata naming Oruka Therapeutics, Inc.
- Check subsequent GENETIC-AF enrollment, DSMB conclusions, trial timing and any changes to the protocol or development plan.
- Assess actual cash burn, cash and marketable-securities balances, and whether the stated runway remains achievable.
- Verify whether additional financing, a collaboration or strategic transaction was obtained, and the resulting dilution or other obligations.
- Review regulatory requirements and progress for both Gencaro and its companion diagnostic, as well as the potential license milestones and royalties.